Rhythm Pharmaceuticals, the developer of setmelanotide, has successfully pursued regulatory approval for the drug (marketed as IMCIVREE) in conditions caused by upstream defects in the MC4R pathway, such as POMC and LEPR deficiencies, where the receptor itself is intact, and the agonist mechanism is highly effective [57]
Table 1 summarizes the RCTs that measured the weight-reducing effects and the other secondary outcomes of GLP-1RA in PCOS patients
doi:10.1210/endo.135.5.7956929 288
GLP-1 antagonists help you feel fuller for longer by slowing digestion and reducing appetite, making it easier to consume fewer calories and lose weight
Quality seems very goodI noticed improved recovery and better performance within a few weeks
Serious but Less Common Side Effects While rare, some symptoms require immediate attention: Severe abdominal pain (possible pancreatitis) Signs of gallbladder issues Allergic reactions (swelling, breathing difficulty) Low blood sugar (especially with insulin use) The U.S